The Company is now positioning itself to further advance Brilacidin, most immediately, in its planned Phase 3 Oral Mucositis program, and in mid-stage testing for Inflammatory Bowel Disease.

Then this same PR- In other news, the Company will commence Scientific Advice discussions with the European Medicines Agency (EMA) this week, via a scheduled meeting, to review plans for the international Phase 3 Brilacidin Oral Mucositis program.

"most immediately" makes it sounds like US P3 preparations ready to start now independent of EU plans. Hopefully big news next week. Really exciting.